Envista/$NVST

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Envista

Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

Ticker

$NVST
Sector

Primary listing

NYSE

Employees

12,300

Envista Metrics

BasicAdvanced
$3.2B
61.62
$0.31
1.01
-

What the Analysts think about Envista

Analyst ratings (Buy, Hold, Sell) for Envista stock.

Bulls say / Bears say

Envista posted Q2 2025 GAAP revenue of $682 million, up 7.7% year-over-year, with core sales growing 5.6%—beating estimates by 6.6%. Management raised full-year 2025 guidance for core sales growth to 3%–4% and adjusted EPS to $1.05–$1.15 (Investing.com)
Adjusted EBITDA jumped 34% to $84 million, with a 240 basis point increase in the adjusted EBITDA margin to 12.4%, highlighting strong operational leverage and pricing strength (Investing.com)
The Specialty Products & Technologies segment achieved 4.7% core sales growth and boosted its adjusted operating margin to 13.5% (up over 400 basis points year-over-year), led by double-digit growth in the Spark clear aligner business—demonstrating accelerating adoption of high-margin products (Investing.com)
Operating cash flow dropped 33% to $89 million in the first half of 2025, signaling weaker cash conversion and potential strain on working capital, even as profits increased (Panabee)
China’s Volume-Based Procurement reforms have created major pricing pressure and revenue declines in both the orthodontics (Brackets & Wires) and implant businesses, raising uncertainty over recovery prospects in the region (Simply Wall Street)
Tariffs are expected to add $15–$20 million in costs during the second half of 2025, while continued transactional foreign exchange losses remain a significant drag on margins, despite mitigation efforts (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Envista Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Envista Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVST

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs